Johnson & Johnson Files 2024 10-K
Ticker: JNJ · Form: 10-K · Filed: 2025-02-13T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
JNJ dropped its 2024 10-K. Full financials and biz details inside.
AI Summary
Johnson & Johnson filed its 2024 10-K report on February 13, 2025, detailing its fiscal year ending December 29, 2024. The company, headquartered in New Brunswick, NJ, operates in the Pharmaceutical Preparations sector. Key financial details and operational highlights for the fiscal year are presented within this comprehensive filing.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of Johnson & Johnson's financial performance, strategic initiatives, and risk factors for the 2024 fiscal year, crucial for understanding the company's current standing and future outlook.
Risk Assessment
Risk Level: medium — 10-K filings inherently carry medium risk due to the detailed financial and operational information that can impact stock valuation.
Key Players & Entities
- JOHNSON & JOHNSON (company) — Filer of the 10-K
- 2024-12-29 (date) — Fiscal year end date
- 2025-02-13 (date) — Filing date
- New Brunswick, NJ (location) — Company headquarters
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What was Johnson & Johnson's fiscal year end for this filing?
The fiscal year end was December 29, 2024.
When was this 10-K filed with the SEC?
This 10-K was filed on February 13, 2025.
What is Johnson & Johnson's primary industry classification?
Johnson & Johnson's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Where is Johnson & Johnson headquartered?
Johnson & Johnson is headquartered in New Brunswick, NJ.
What is the accession number for this filing?
The accession number for this filing is 0000200406-25-000038.
From the Filing
0000200406-25-000038.txt : 20250213 0000200406-25-000038.hdr.sgml : 20250213 20250213160739 ACCESSION NUMBER: 0000200406-25-000038 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 168 CONFORMED PERIOD OF REPORT: 20241229 FILED AS OF DATE: 20250213 DATE AS OF CHANGE: 20250213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03215 FILM NUMBER: 25620252 BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 10-K 1 jnj-20241229.htm 10-K jnj-20241229 0000200406 2024 FY false Johnson & Johnson http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#AccountsPayableCurrent http://fasb.org/us-gaap/2024#AccountsPayableCurrent P25Y http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense iso4217:USD xbrli:shares iso4217:USD xbrli:shares jnj:Employee xbrli:pure jnj:Segment iso4217:EUR iso4217:GBP jnj:StockBasedCompensationPlans jnj:segment jnj:claimant jnj:cases 0000200406 2024-01-01 2024-12-29 0000200406 us-gaap:CommonStockMember 2024-01-01 2024-12-29 0000200406 jnj:A1.150NotesDueNovember2028Member 2024-01-01 2024-12-29 0000200406 jnj:A3.20NotesDueNovember2032Member 2024-01-01 2024-12-29 0000200406 jnj:A1.650NotesDue2035Member 2024-01-01 2024-12-29 0000200406 jnj:A3.350NotesDueNovember2036Member 2024-01-01 2024-12-29 0000200406 jnj:A3.550NotesDueNovember2044Member 2024-01-01 2024-12-29 0000200406 2024-06-30 0000200406 2025-02-06 0000200406 2024-12-29 0000200406 2023-12-31 0000200406 2023-01-02 2023-12-31 0000200406 2022-01-03 2023-01-01 0000200406 2022-01-02 0000200406 us-gaap:RetainedEarningsMember 2022-01-02 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-02 0000200406 us-gaap:CommonStockMember 2022-01-02 0000200406 us-gaap:TreasuryStockCommonMember 2022-01-02 0000200406 us-gaap:RetainedEarningsMember 2022-01-03 2023-01-01 0000200406 us-gaap:TreasuryStockCommonMember 2022-01-03 2023-01-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-03 2023-01-01 0000200406 2023-01-01 0000200406 us-gaap:RetainedEarningsMember 2023-01-01 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 0000200406 us-gaap:CommonStockMember 2023-01-01 0000200406 us-gaap:TreasuryStockCommonMember 2023-01-01 0000200406 us-gaap:RetainedEarningsMember 2023-01-02 2023-12-31 0000200406 us-gaap:TreasuryStockCommonMember 2023-01-02 2023-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-02 2023-12-31 0000200406 us-gaap:RetainedEarningsMember 2023-12-31 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000200406 us-gaap:CommonStockMember 2023-12-31 0000200406 us-gaap:TreasuryStockCommonMember 2023-12-31 0000200406 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-29 0000200406 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-29 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-29 0000200406 us-gaap:RetainedEarningsMember 2024-12-29 0000200406 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 0000200406 us-gaap:CommonStockMember 2024-12-29 0000200406 us-gaap:TreasuryStockCommonMember 2024-12-29 0000200406 us-gaap:IPOMember jnj:KenvueIncMember 2023-05-08 2023-05-08